Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
Femasys Inc. (FEMY), a biomedical company focusing on women's health, announces its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 at the Lotte New York Palace Hotel. Kathy Lee-Sepsick, Founder, President, and CEO of Femasys, will engage in a fireside chat hosted by Emily Bodnar, Life Sciences Analyst.
The presentation will be available on-demand starting September 9, 2024, at 7:00 AM ET. Investors can access the webcast through the provided link or the investor relations section of the Femasys website. The replay will be available for approximately 90 days after the event. Additionally, Kathy Lee-Sepsick and CFO Dov Elefant will be available for one-on-one meetings throughout the conference.
Femasys Inc. (FEMY), un'azienda biomedicale focalizzata sulla salute delle donne, annuncia la sua partecipazione alla 26a Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. L'evento si svolgerà dal 9 all'11 settembre 2024 presso il Lotte New York Palace Hotel. Kathy Lee-Sepsick, Fondatrice, Presidente e CEO di Femasys, parteciperà a una chiacchierata informale moderata da Emily Bodnar, Analista delle Scienze della Vita.
La presentazione sarà disponibile on-demand a partire dal 9 settembre 2024, alle 7:00 AM ET. Gli investitori possono accedere al webcast tramite il link fornito o la sezione relazioni con gli investitori del sito web di Femasys. La replica sarà disponibile per circa 90 giorni dopo l'evento. Inoltre, Kathy Lee-Sepsick e il CFO Dov Elefant saranno disponibili per incontri individuali durante tutta la conferenza.
Femasys Inc. (FEMY), una empresa biomédica centrada en la salud de la mujer, anuncia su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El evento tendrá lugar del 9 al 11 de septiembre de 2024 en el Lotte New York Palace Hotel. Kathy Lee-Sepsick, Fundadora, Presidenta y CEO de Femasys, participará en una charla informal moderada por Emily Bodnar, Analista de Ciencias de la Vida.
La presentación estará disponible on-demand a partir del 9 de septiembre de 2024, a las 7:00 AM ET. Los inversores pueden acceder al webcast a través del enlace proporcionado o la sección de relaciones con inversores en el sitio web de Femasys. La repetición estará disponible durante aproximadamente 90 días después del evento. Además, Kathy Lee-Sepsick y el CFO Dov Elefant estarán disponibles para reuniones individuales durante toda la conferencia.
Femasys Inc. (FEMY), 여성 건강에 중점을 둔 생물 의학 회사, H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 Lotte New York Palace Hotel에서 열릴 예정입니다. Kathy Lee-Sepsick, Femasys의 설립자, 회장 및 CEO는 생명 과학 분석가인 Emily Bodnar가 주최하는 편안한 대화에 참여할 것입니다.
발표 내용은 2024년 9월 9일 오전 7시 ET부터 주문형으로 제공될 예정입니다. 투자자는 제공된 링크 또는 Femasys 웹사이트의 투자자 관계 섹션을 통해 웹캐스트에 접근할 수 있습니다. 재생은 행사 종료 후 약 90일 동안 사용할 수 있습니다. 또한, Kathy Lee-Sepsick와 CFO Dov Elefant는 회의 기간 동안 일대일 미팅을 위해 available 합니다.
Femasys Inc. (FEMY), une entreprise biomédicale axée sur la santé des femmes, annonce sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'événement aura lieu du 9 au 11 septembre 2024 au Lotte New York Palace Hotel. Kathy Lee-Sepsick, Fondatrice, Présidente et CEO de Femasys, participera à une discussion informelle animée par Emily Bodnar, Analyste en Sciences de la Vie.
La présentation sera disponible en mode à la demande à partir du 9 septembre 2024, à 7h00 ET. Les investisseurs peuvent accéder au webcast via le lien fourni ou la section relations avec les investisseurs du site web de Femasys. La rediffusion sera disponible pendant environ 90 jours après l'événement. De plus, Kathy Lee-Sepsick et le CFO Dov Elefant seront disponibles pour des réunions individuelles tout au long de la conférence.
Femasys Inc. (FEMY), ein biomedizinisches Unternehmen, das sich auf die Gesundheit von Frauen konzentriert, gibt seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt. Die Veranstaltung findet vom 9. bis 11. September 2024 im Lotte New York Palace Hotel statt. Kathy Lee-Sepsick, Gründerin, Präsidentin und CEO von Femasys, wird in einem ungezwungenen Gespräch, das von Emily Bodnar, Analystin für Lebenswissenschaften, moderiert wird, teilnehmen.
Die Präsentation wird ab dem 9. September 2024 um 7:00 Uhr ET auf Abruf verfügbar sein. Investoren können über den bereitgestellten Link oder den Bereich für Investorenbeziehungen auf der Femasys-Website auf das Webcast zugreifen. Die Wiederholung wird etwa 90 Tage nach der Veranstaltung verfügbar sein. Zudem werden Kathy Lee-Sepsick und CFO Dov Elefant während der gesamten Konferenz für Einzelgespräche zur Verfügung stehen.
- None.
- None.
ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference. The fireside chat will be hosted by Emily Bodnar, Life Sciences Analyst. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel.
| Presentation Date: | September 9, 2024 |
| Time: | Available on-demand starting at 7:00 AM ET |
| Webcast Link: | |
| https://journey.ct.events/view/40d58b25-f692-4267-996d-eb0cf50146ec | |
A webcast of the presentation can be accessed on the investor relations section of the Femasys website. A replay of the webcast will be archived and available following the event for approximately 90 days.
https://ir.femasys.com/events-and-presentations/default.aspx
Kathy Lee-Sepsick and Dov Elefant, Chief Financial Officer, will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click below:
https://hcwevents.com/annualconference/
About Femasys
Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, Europe, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® and FemVue® Mini for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
CORE IR
Matt Blaise
IR@femasys.com
Media:
CORE IR
Kati Waldenburg
Media@femasys.com
FAQ
When is Femasys (FEMY) participating in the H.C. Wainwright Global Investment Conference?
Who will represent Femasys (FEMY) at the H.C. Wainwright conference?
Where can investors access the Femasys (FEMY) presentation from the H.C. Wainwright conference?
What is the focus of Femasys (FEMY) as a company?
